Evaluating CPAP Therapy to Prevent Atrial Fibrillation Return After Catheter Ablation in Patients with Obstructive Sleep Apnea

What this Trial Is About

Atrial fibrillation AF is a common heart rhythm disorder with a significant chance of returning after catheter ablation treatment. This trial studies adults aged 18 to 75 who have persistent AF and obstructive sleep apnea OSA to see if using continuous positive airway pressure CPAP therapy after ablation reduces AF recurrence. The trial is a randomized, open-label study conducted at multiple centers in China to evaluate the effect of CPAP on AF outcomes over 12 months. Participants are randomly assigned to either the CPAP group, which uses a CPAP device for 12 months with treatment settings adjusted by pressure titration, or the usual care group, which receives standard AF treatment and education about OSA without CPAP provided. CPAP adherence is monitored through device data, and participants in both groups receive guideline-based medical therapy for AF. Additional OSA treatments outside the study may be used and recorded. Throughout the 12 months, participants will wear ambulatory ECG monitors for seven days at 3, 6, 9, and 12 months to detect arrhythmia recurrence. Follow-up visits occur at 1, 3, 6, and 12 months in person or by phone to check health status and treatment progress. Researchers will measure freedom from atrial arrhythmia recurrence as the primary outcome and assess other factors like arrhythmia patterns, medication use, quality of life, and psychological health.

Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation